Iodine-131 radioembolization boosts the immune activation enhanced by icaritin/resiquimod in hepatocellular carcinoma

作者：Xinyi Li, Yuyi Qian, Xin Lu, Mingzhen Xu, Simin He, Jianping Zhang, Shaoli Song · 发表于：Journal of Controlled Release · 年份：2024 · DOI：10.1016/j.jconrel.2024.12.064 · 被引用次数：10 · 研究领域：Immunotherapy and Immune Responses、Cancer Mechanisms and Therapy、Immune Cell Function and Interaction

I-ICT/R848-MS embolization brought significant immune activation, where the ratio of cytotoxic T lymphocytes to regulatory T cells in tumor sites upregulated from 1.75 ± 0.20 to 24.31 ± 1.79, and DC maturation in lymph nodes increased from 8.90 ± 1.51 % to 34.70 ± 3.12 %. Enhanced anti-tumor efficacy with no relapse was proved in rat orthotopic N1S1 HCC models. These results demonstrated the great potential of this multifunctional embolic agent to treat HCC through transarterial radio-immuno-chemoembolization (TARICE).